Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

BACKGROUND: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Cinieri, Saverio, Gasparro, Donatello, Bordonaro, Roberto, Guglielmini, Pamela Francesca, Chiuri, Vincenzo Emanuele, D'Angelillo, Rolando M, Ceresoli, Giovanni Luca, Fagnani, Daniele, Acquati, Mirko, Mencoboni, Manlio, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Panebianco, Fabiana, Beccaglia, Patrizia, Procopio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779770/
https://www.ncbi.nlm.nih.gov/pubmed/33425672
http://dx.doi.org/10.1016/j.jbo.2020.100341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779770/
https://www.ncbi.nlm.nih.gov/pubmed/33425672
http://dx.doi.org/10.1016/j.jbo.2020.100341

Ejemplares similares